Montplaisir J, Godbout R
Sleep. 1986;9(1 Pt 2):280-4. doi: 10.1093/sleep/9.1.280.
Zimelidine, a selective inhibitor of serotonin (5-HT) reuptake in the CNS, was administered to narcoleptic patients. This medication has a potent anticataplectic action without improving daytime somnolence. These results suggest that 5-HT neuronal systems are involved in the physiopathology of cataplexy. Zimelidine, however, has no anticholinergic effect, so it is unlikely that cholinergic mechanisms thought to be important in animal cataplexy would play a major role in human cataplexy. In addition, zimelidine had no effect on nocturnal sleep patterns of these patients which is surprising considering the importance of 5-HT neuronal systems in sleep physiology. A 5-HT hypothesis of cataplexy is formulated, and the mechanisms of action of other anticataplectic agents are discussed.
齐美利定是一种中枢神经系统中5-羟色胺（5-HT）再摄取的选择性抑制剂，被用于治疗发作性睡病患者。这种药物具有强大的抗猝倒作用，但并不能改善日间嗜睡症状。这些结果表明，5-HT神经元系统参与了猝倒的病理生理过程。然而，齐美利定没有抗胆碱能作用，因此，被认为在动物猝倒中起重要作用的胆碱能机制不太可能在人类猝倒中起主要作用。此外，齐美利定对这些患者的夜间睡眠模式没有影响，鉴于5-HT神经元系统在睡眠生理学中的重要性，这一结果令人惊讶。本文提出了猝倒的5-HT假说，并讨论了其他抗猝倒药物的作用机制。
